How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

October 22, 2026

Early Release – Isolation of Orientia tsutsugamushi from Bat-Associated Chiggers, Japan – Volume 32, Number 12—December 2026 – Emerging Infectious Diseases journal

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected

October 22, 2026 No Comments

[Clinical Picture] Mucocutaneous leishmaniasis caused by Leishmania infantum in a Norwegian patient receiving TNF-α inhibitor therapy

A 56-year-old man, a lifelong resident of Norway, had received methotrexate for the past 15

October 22, 2026 No Comments

Ebola Bundibugyo Virus Disease in Kenya – Level 1 – Level 1 – Practice Usual Precautions – Travel Health Notices | Travelers’ Health

Bundibugyo virus disease (BVD) is a rare and potentially deadly type of viral hemorrhagic fever. BVD

October 22, 2026 No Comments

Early Release – Isolation of Orientia tsutsugamushi from Bat-Associated Chiggers, Japan – Volume 32, Number 12—December 2026 – Emerging Infectious Diseases journal

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected

October 22, 2026 No Comments

Early Release – Isolation of Orientia tsutsugamushi from Bat-Associated Chiggers, Japan – Volume 32, Number 12—December 2026 – Emerging Infectious Diseases journal

[Clinical Picture] Mucocutaneous leishmaniasis caused by Leishmania infantum in a Norwegian patient receiving TNF-α inhibitor therapy

Ebola Bundibugyo Virus Disease in Kenya – Level 1 – Level 1 – Practice Usual Precautions – Travel Health Notices | Travelers’ Health

Hantavirus spike structure reveals recessed protocadherin-1 binding pocket

Epidemics linked to loss of health workers, with poorer nations hardest hit

Infectious disease specialists protest HIV funding cuts

Early Release – Isolation of Orientia tsutsugamushi from Bat-Associated Chiggers, Japan – Volume 32, Number 12—December 2026 – Emerging Infectious Diseases journal

Schedule an Appointment

Quick Links

Patient Forms

Contact Us